Bench-to-bedside review: The role of C1-esterase inhibitor in sepsis and other critical illnesses

The purpose of this bench-to-bedside review is to summarize the literature relating to complement activation in sepsis and other critical illnesses and the role of C1-esterase inhibitor (C1 INH) as a potential therapy.

• Publication year

  2011

• Venue

  Critical Care

• Publication date

  2011-01-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/cc9304PMID 21345278PMCID 3222011
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Eculizumab in Paroxysmal Nocturnal Haemoglobinuria

  2012cited by this paper
• C1 inhibitor level on neonatal sepsis and its relations with clinical findings

  2010influential reference
• Sepsis, complement and the dysregulated inflammatory response

  2009cited by this paper
• Eculizumab for paroxysmal nocturnal haemoglobinuria.

  2009cited by this paper
• [Safety and efficacy of purified human C1-esterase inhibitor in the treatment of patients with sepsis].

  2009cited by this paper
• [Safety and efficacy of purified human C1-esterase inhibitor in the treatment of patients with sepsis].

  2009cited by this paper
• Functions of the complement components C3 and C5 during sepsis

  2008cited by this paper
• Biological activities of C1 inhibitor.

  2008influential reference
• Harmful molecular mechanisms in sepsis

  2008cited by this paper
• Role of the complement in experimental sepsis

  2008influential reference
• Acute pancreatitis.

  2008cited by this paper
• The effect of C1 inhibitor on intestinal ischemia and reperfusion injury.

  2008cited by this paper
• Functional roles for C5a receptors in sepsis

  2008cited by this paper
• The spectrum and treatment of angioedema.

  2008cited by this paper
• Complement: an efficient sword of innate immunity.

  2008cited by this paper
• Sepsis, apoptosis and complement.

  2008cited by this paper
• C1 Inhibitor-Mediated Protection from Sepsis

  2007cited by this paper
• Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reperfusion: a randomised double-blind study.

  2007cited by this paper
• C1 Inhibitor Serpin Domain Structure Reveals the Likely Mechanism of Heparin Potentiation and Conformational Disease*

  2007cited by this paper
• C1 Inhibitor-Mediated Protection from Sepsis1

  2007cited by this paper
• C1 inhibitor treatment improves host defense in pneumococcal meningitis in rats and mice.

  2007cited by this paper
• Nonallergic angioedema: role of bradykinin

  2007cited by this paper
• C1 inhibitor: biologic activities that are independent of protease inhibition.

  2007cited by this paper
• C 1 Inhibitor Treatment Improves Host Defense in Pneumococcal Meningitis in Rats and Mice

  2007cited by this paper
• Hyperacute rejection in ex vivo‐perfused porcine lungs transgenic for human complement regulatory proteins

  2006cited by this paper
• Anti-ischemia/reperfusion of C1 inhibitor in myocardial cell injury via regulation of local myocardial C3 activity.

  2006cited by this paper
• Anti-apoptotic role for C1 inhibitor in ischemia/reperfusion-induced myocardial cell injury.

  2006cited by this paper
• C5a, a therapeutic target in sepsis.

  2006cited by this paper
• Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction.

  2006cited by this paper
• An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction

  2006cited by this paper
• Complement-induced impairment of the innate immune system during sepsis

  2005cited by this paper
• A Direct Role for C1 Inhibitor in Regulation of Leukocyte Adhesion 1

  2005cited by this paper
• [Acute pancreatitis].

  2004cited by this paper
• Effects of C1 esterase inhibitor administration on intestinal functional capillary density, leukocyte adherence and mesenteric plasma extravasation during experimental endotoxemia

  2004cited by this paper
• C1-inhibitor reduces hepatic leukocyte-endothelial interaction and the expression of VCAM-1 in LPS-induced sepsis in the rat.

  2004cited by this paper
• C1 Inhibitor Prevents Endotoxin Shock Via a Direct Interaction with Lipopolysaccharide 1 2

  2003cited by this paper
• Administration of C1 Inhibitor Reduces Neutrophil Activation in Patients with Sepsis

  2003cited by this paper
• Effect of complement fragment 1 esterase inhibition on survival of human decay-accelerating factor pig lungs perfused with human blood.

  2003cited by this paper
• Review of Medical Microbiology and Immunology

  2002cited by this paper
• Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction.

  2002cited by this paper
• C1-inhibitor for therapy and prophylaxis of acute vascular rejection of porcine kidneys in cynomolgus monkeys.

  2002cited by this paper
• C1 inhibitor for prophylaxis of xenograft rejection after pig to cynomolgus monkey kidney transplantation.

  2002cited by this paper
• C1-inhibitor for prophylaxis of xenograft rejection after pig to cynomolgus monkey kidney transplantation.

  2002cited by this paper
• C1-inhibitor in patients with severe sepsis and septic shock: Beneficial effect on renal dysfunction

  2002cited by this paper
• Ex-vivo hemoperfusion (eHPS) of pig-lungs with whole human blood: effects of complement inhibition with a soluble C1-esterase-inhibitor.

  2001cited by this paper
• Complement factor C5a exerts an anti-inflammatory effect in acute pancreatitis and associated lung injury.

  2001cited by this paper
• Pathogenesis of Cerebral Malaria: Recent Experimental Data and Possible Applications for Humans

  2001cited by this paper
• Application of C1-Esterase Inhibitor During Reperfusion of Ischemic Myocardium: Dose-Related Beneficial Versus Detrimental Effects

  2001cited by this paper
• C1 inhibitor prevents capillary leakage after thermal trauma

  2000cited by this paper
• C1-esterase inhibitor in graft failure after lung transplantation

  1999influential reference
• C1-inhibitor attenuates hyperacute rejection and inhibits complement, leukocyte and platelet activation in an ex vivo pig-to-human perfusion model.

  1999cited by this paper
• Combined antithrombin III and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coli endotoxin.

  1999cited by this paper
• Influence of C1-esterase inhibitor on tissue oxygenation of jejunal mucosa during endotoxemia.

  1999cited by this paper
• Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury.

  1998cited by this paper
• Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA

  1998cited by this paper
• Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock.

  1998cited by this paper
• Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement.

  1997cited by this paper
• Postburn edema and related changes in interleukin-2, leukocytes, platelet activation, endothelin-1, and C1 esterase inhibitor.

  1997influential reference
• Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion.

  1997cited by this paper
• C1 esterase inhibitor concentrate for capillary leakage syndrome following bone marrow transplantation

  1997cited by this paper
• Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion.

  1995cited by this paper
• Effects of C1-esterase inhibitor in three models of acute pancreatitis

  1995cited by this paper
• In vitro activation of the classical pathway of complement by a streptococcal lipoteichoic acid.

  1994cited by this paper
• Initial studies on the administration of C1-esterase inhibitor to patients with septic shock or with a vascular leak syndrome induced by interleukin-2 therapy.

  1994cited by this paper
• Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1 inhibitor.

  1993cited by this paper
• Endotoxin-induced pulmonary dysfunction is prevented by C1-esterase inhibitor.

  1993cited by this paper
• Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1 inhibitor.

  1993cited by this paper
• Complement activation during liver transplantation.

  1993cited by this paper
• C1-esterase inhibitor substitution in sepsis.

  1992cited by this paper
• Interpretation of the metabolic effects of trauma and sepsis.

  1987cited by this paper
• The complement system in sepsis and trauma.

  1985cited by this paper
• Complement-mediated opsonic activity in normal and infected human cerebrospinal fluid: early response during bacterial meningitis.

  1982cited by this paper
• [On acute pancreatitis].

  1967cited by this paper
• Hereditary angioneurotic edema: II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein

  1962cited by this paper
• HEREDITARY ANGIO‐NEUROTIC ŒDEMA

  1888cited by this paper

• Cardiometabolic shock: understanding the final turns of the downward spiral

  2025cites this paper
• Recent Advances in Pathogenesis and Anticoagulation Treatment of Sepsis-Induced Coagulopathy

  2025cites this paper
• Diagnostic and therapeutic value of human serpin family proteins.

  2024cites this paper
• Effects of C1-INH Treatment on Neurobehavioral Sequelae and Late Seizures After Traumatic Brain Injury in a Mouse Model of Controlled Cortical Impact

  2023cites this paper
• Targeting thromboinflammation in COVID-19 – A narrative review of the potential of C1 inhibitor to prevent disease progression

  2022cites this paper
• C1-inhibitor influence on platelet activation by thrombin receptors agonists

  2022cites this paper
• C1-Inhibitor: Structure, Functional Diversity and Therapeutic Development.

  2021cites this paper
• Disseminated intravascular coagulation and its immune mechanisms

  2021cites this paper
• Identification of Human Kinin-Forming Enzyme Inhibitors from Medicinal Herbs

  2021cites this paper
• Revisiting the complement system in systemic lupus erythematosus

  2020cites this paper
• Role of Complement and Histones in Sepsis

  2020cites this paper
• A Review of Neutrophil Extracellular Traps (NETs) in Disease: Potential Anti-NETs Therapeutics

  2020cites this paper
• Targeted donor complement blockade after brain death prevents delayed graft function in a nonhuman primate model of kidney transplantation

  2020cites this paper
• C1 esterase inhibitor activity is reduced in the acute phase following burn injury: a prospective observational study.

  2019cites this paper
• Protein-based cardiogenic shock patient classifier.

  2019cites this paper
• The role of complement and Toll-like receptors in thromboinflammation

  2019influential citation
• Metabolic response to maxillofacial trauma revisited: A retrospective study

  2019cites this paper
• The core genes involved in the promotion of depression in patients with ovarian cancer

  2019cites this paper
• In vitro characterisation of the complement cascade for predicting patient outcome post-operatively

  2019cites this paper
• НОВЫЕ АСПЕКТЫ ПАТОГЕНЕЗА СЕПСИСА И СЕПТИЧЕСКОГО ШОКА У ДЕТЕЙ. СИСТЕМА КОМПЛЕМЕНТА КАК МИШЕНЬ ДЛЯ ЭФФЕКТИВНОЙ ТЕРАПИИ

  2018cites this paper
• Serial change of C1 inhibitor in patients with sepsis: a prospective observational study

  2018cites this paper
• Serial change of C1 inhibitor in patients with sepsis--a preliminary report.

  2016cites this paper
• Polyphosphate is a novel cofactor for regulation of complement by a serpin, C1 inhibitor.

  2016cites this paper
• C1-inhibitor efficiently delays clot development in normal human whole blood and inhibits Escherichia coli-induced coagulation measured by thromboelastometry.

  2016cites this paper
• Regulation of Complement and Contact System Activation via C1 Inhibitor Potentiation and Factor XIIa Activity Modulation by Sulfated Glycans – Structure-Activity Relationships

  2016cites this paper
• Antithrombin III, but not C1 esterase inhibitor reduces inflammatory response in lipopolysaccharide-stimulated human monocytes in an ex-vivo whole blood setting.

  2014cites this paper
• Successful use of daily intravenous infusion of C1 esterase inhibitor concentrate in the treatment of a hereditary angioedema patient with ascites, hypovolemic shock, sepsis, renal and respiratory failure

  2014cites this paper
• Role of the kallikrein–kinin system in traumatic brain injury

  2014cites this paper
• Phénotypes biologiques de l'angioedème à kinine

  2014cites this paper
• C1-Esterase Inhibitor: Biological Activities and Therapeutic Applications

  2013cites this paper
• C1 Inhibitor Suppresses the Endotoxic Activity of a Wide Range of Lipopolysaccharides and Interacts With Live Gram-negative Bacteria

  2012cites this paper
• [Successful use of C1 esterase inhibitor in capillary leak syndrome].

  2012cites this paper
• Bench-to-bedside review: Immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective

  2012cites this paper
• Erfolgreiche Anwendung von C1-Esterase-Inhibitor bei „capillary leak syndrome“

  2012cites this paper
• Complement deficiency states and associated infections.

  2011cites this paper